Funded by the Food and Drug Administration, the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) has just been launched. The resource is intended to accelerate rare disease research. Approved investigators will have access to deidentified patient-level data.
“RDCA-DAP promotes the sharing of existing patient-level data and encourages the standardization of new data collection. By integrating data in a format suitable for analytics, RDCA-DAP accelerates the understanding of disease progression (including sources of variability to optimize the characterization of subpopulations), clinical outcome measures and biomarkers, and facilitates the development of mathematical models of disease and innovative clinical trial designs.” Learn more about the portal here.
(Source: RDCA-DAP, 2021)